Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Starpharma: Products, Deals and Forecasts




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Starpharma: Products, Deals and Forecasts
Released on: December 29, 2009. © PharmaVentures Ltd
Visitors: You are watching a 30 seconds preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks with Jackie Fairley, Chief Executive Officer at Starpharma.

Filmed at AusBiotech 2009, they discuss:

• Starpharma's new technology and its applications
• Starpharma's anti-viral Vivagel and its global rights
• the deal with Eli Lilly's animal health division
• Starpharma's business model
• the prospects of Starpharma taking products to market without outside help
• Starpharma's future revenue streams and the outlook for 2010
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Star Pharma's new technology and its applications.
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here in Melbourne, Australia. On this show I have Jackie Fairley, who is CEO of a company called Star Pharma , which is based here in Melbourne, in Australia. Welcome.
Jackie Fairly:
Thank you.
Fintan Walton:
Jackie Fairly , you've been on the show before talking about Star Pharma you're company that has a platform technology, that technology is a dendrimer-technology. Tell us little bit more about that technology, but also some of the recent success stories you've had?
Jackie Fairly:
Sure. So our technology is a particular type of synthetic macromolecule called adendrimer so a nanoscale particle if you like and it can applied against the whole range of different product categories, we have deals currently with Siemens Healthcare for its use in diagnostics. And we've recently signed some new deals for its application in drug delivery with Eli Lilly's animal health division Elanco and also part of GSK for using dermatology. It can also be applied in a range of industrial areas such as agrochemicals, chemicals and laboratory reagents. And we also have a lead product which is in clinical development as a pharmaceutical.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Jackie Fairley
Chief Executive Officer
Starpharma

Starpharma

Starpharma is a world leader in the development of nanotechnology-based pharmaceuticals and, through its US-based subsidiary Dendritic Nanotechnologies (DNT), a range of life-science and industrial uses.